Investorideas.com newswire, breaking biotechnology and pharma news

Tuesday, September 16, 2014

Aethlon Medical, Inc. (OTCQB: AEMD) - "The Identification of Neurological Disorders in NFL Players"

Medical Technology Breaking News: Aethlon Medical, Inc. (OTCQB: AEMD) - "The Identification of Neurological Disorders in NFL Players"

New York, NY - September 16, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD) today published a new blog post on The Chairman’s Blog, written by the Company’s Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his new blog, Mr. Joyce expands on the Exosome Sciences blood-based "liquid biopsy" to potentially identify and monitor CTE in a living person. Mr. Joyce reflects on the impact this diagnostic can have on the future of advancing candidate therapies to treat CTE and what this can mean for Aethlon Medical and its subsidiary Exosome Sciences. Read the full blog post from Mr. Joyce on TheChairmansBlog.com.


About Aethlon Medical
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com 

About TheChairmansBlog.com
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: The Charimans Blog

Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more...







Tuesday, September 9, 2014

GenSpera (OTCQB:GNSZ) Receives Patent on Prodrug Targeted for Prostate Cancer

Biotech News Alert: GenSpera (OTCQB:GNSZ) Receives Patent on Prodrug Targeted for Prostate Cancer

SAN ANTONIO - September 9, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs."

The patent covers the composition of a specific prodrug activated by Prostate Specific Antigen (PSA) that is designed to deliver a thapsigargin derivative selectively to prostate cancers. PSA is an enzyme secreted by prostate cancer cells. A derivative of thapsigargin, 12ADT, is the active component of mipsagargin (G-202), GenSpera's lead drug candidate in Phase II clinical trials for glioblastoma (brain cancer) patients and for hepatocellular carcinoma (liver cancer) patients after sorafenib (Nexavar®) therapy. GenSpera currently owns or licenses 13 issued patents overall with 10 relating to prostate cancer.

"The issuance of this patent further strengthens our intellectual property position for targeted anti-cancer prodrugs and recognizes their unique applicability in treating prostate cancer," commented GenSpera CEO, Craig Dionne, PhD "Each year over 230,000 men are diagnosed with prostate cancer in the United States alone and approximately 30,000 men die of the disease. The market for prostate cancer drugs is estimated to be $6.7 billion by the year 2020. Current treatment options are dominated by drugs that work via chemical castration of the patient. It is important that we develop safe and effective drugs for these men without the very significant side effects of current treatments."


About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types.

Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

Company presentations are available at: http://www.genspera.com

Watch the Corporate Video: http://youtu.be/jULjEul-mBk

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

CONTACT:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.  (210) 479-8112                                     

Investors: 
Steve Gersten
Capital Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920

Media:
Dawn Van Zant
(800) 665 0411

Visit this company: www.genspera.com

More info on GNSZ at Investorideas.com Visit: http://www.investorideas.com/CO/GNSZ/

Disclaimer/Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18, 2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/




Monday, September 8, 2014

GenSpera (OTCQB:GNSZ) Presents Mipsagargin (G-202) HCC Clinical Trial Update at 8th International Liver Cancer Association Conference

Biotech News Alert: GenSpera (OTCQB:GNSZ) Presents Mipsagargin (G-202) HCC Clinical Trial Update at 8th International Liver Cancer Association Conference

50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months

SAN ANTONIO - September 8, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8th International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD, will discuss these results in further detail during the Company's presentation at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9th at 12:05 p.m. Eastern.

GenSpera presented a poster containing interim results from the Phase Ib and ongoing Phase II study in HCC patients who had previously progressed on, or who were intolerant of, sorafenib, a drug co-developed and co-marketed by Bayer and Onyx Pharmaceuticals. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 50% of patients exhibited stable disease (no tumor growth) at 4 months on study.

"Mipsagargin is differentiated from most other drugs being tested in HCC due to its well-tolerated safety profile and the significant proportion of patients that experience prolonged disease stabilization while on treatment," stated Dr. Craig Dionne, GenSpera CEO. "Liver cancer is the third largest cancer killer worldwide and is expected to represent a $1.5 billion market by 2019. We are encouraged by these early stage positive results and what they imply for our ongoing and planned Phase II clinical trials for mipsagargin in glioblastoma, prostate cancer and renal cell carcinoma patients."

Investors can view the poster at the Company website: www.genspera.com

Rodman & Renshaw 16th Annual Global Investment Conference Details:
When: Tuesday, September 9th at 12:05 p.m. Eastern
Where: The New York Palace Hotel in New York City

About: www.rodm.com

To arrange a one-on-one meeting with management, please contact Steve Gersten at steve@capmarketsgroup.com.


About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types.

Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

Company presentations are available at: http://www.genspera.com

Watch the Corporate Video: http://youtu.be/jULjEul-mBk

About ILCA 2014
The 8th Annual International Liver Cancer Association Conference was held September 5-7, 2014, at the Hotel Granvia Kyoto in Kyoto, Japan. The International Liver Cancer Association (ILCA) is an international organization devoted exclusively to liver cancer research for experts from all related disciplines. Visit the ILCA website at http://www.ilca2014.org.

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

CONTACT:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.  (210) 479-8112                                     

Investors: 
Steve Gersten
Capital Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920

Media:
Dawn Van Zant
(800) 665 0411

Visit this company: www.genspera.com

More info on GNSZ at Investorideas.com Visit: http://www.investorideas.com/CO/GNSZ/

Disclaimer/Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18, 2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.



Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/ 

Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform

SAN DIEGO and PRINCETON, N.J. - September 8, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications. Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders.

In the validation studies, ESI researchers provided evidence that their diagnostic platform could identify the presence of cancer in analyzed blood samples from individuals suffering from glioblastoma, metastatic melanoma, breast cancer, ovarian cancer, colorectal cancer and pancreatic cancer. Beyond the potential implications in diagnosing cancer, ESI researchers believe the high-sensitivity of the platform will allow for effective monitoring of cancer progression and response to corresponding therapies. In oncology indications, the sensitivity of the ESI platform also represents an advancement over the ELLSA assay that was originally developed by Aethlon Medical to quantify changes in circulating exosome load resulting from the administration of Aethlon Hemopurifier® therapy. The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes, which in addition to being an oncology biomarker, suppress the immune system and contribute to the spread of metastasis in cancer patients.

Based on previously reported discoveries related to progressive neurodegenerative disorders, Aethlon further disclosed that the ESI team has initiated follow-on studies to advance a candidate blood test to identify and monitor the progression of Chronic Traumatic Encephalopathy (CTE). At present, CTE is only diagnosed through postmortem autopsy. CTE has been most commonly found at autopsy in former National Football League (NFL) players and has also been demonstrated to be prevalent in soldiers exposed to blast injury.

In previous disclosures, ESI researchers reported that they had successfully isolated brain-specific biomarkers that could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), CTE and Glioblastoma Multiforme (GBM). The studies provided evidence that the ESI platform could also detect exosomes as a basis for a "liquid biopsy" to diagnose neurologic conditions. While exosomes from the central nervous system had previously been identified in the cerebrospinal fluid, the ESI team identified exosomes carrying brain-specific markers tau, beta-amyloid, glycoprotein A2B5 and S100B protein that had been transported across the blood-brain barrier and into the circulatory system.

"I am immensely proud of the ESI research team as their considerable breadth of collected data reinforces the possibility that a single platform could detect and monitor a wide-range of disease conditions," stated Aethlon Medical CEO Jim Joyce, who also serves as Executive Chairman at ESI. Mr. Joyce founded ESI on behalf of Aethlon Medical shareholders as a means to explore if the lectin-affinity techniques underlying Hemopurifier® therapy could provide a basis for proprietary diagnostic applications.

In the oncology platform validation studies, 198 single point serum specimens (taken at the time of cancer diagnosis) were analyzed from patients with Glioblastoma, Metastatic Melanoma, Breast cancer, Ovarian cancer, Colorectal cancer and Pancreatic cancer, plus 20 age-matched, female and male non-cancer controls. In the studies, the ESI platform was consistently able to differentiate individuals afflicted with cancer as compared to non-cancer controls. The tested serum specimens were obtained from commercial and collaborative academic biorepositories. A breakdown of the analyzed cancer specimens include:
·        Glioblastoma – 5 late stage
·        Metastatic Melanoma – 20 late stage
·        Ovarian cancer - 31 early stage and 114 late stage
·        Colorectal cancer – 7 early stage and 7 late stage
·        Pancreatic cancer – 2 early stage and 12 late stage

Based on the data collected, ESI plans to establish collaborations and clinical partnerships to further validate its platform and identify specific oncology and neurodegenerative indications where the platform offers to improve upon standard of care methods to diagnose and monitor disease progression.

Additional study details will be presented at the Exosomes & Single Cell Analysis Summit to be held on September 18th and 19th, 2014.


About Exosome Sciences, Inc.
Exosome Sciences (ESI), a majority wholly owned subsidiary of Aethlon Medical, Inc., develops exosome-based solutions to improve identification and monitoring of acute and chronic conditions. Our candidate products are focused toward diagnostic advancements in the fields of oncology, infectious disease and brain injury. Exosomes represent an optimal diagnostic target as diseased or injured cells release these particles into body fluids such as urine, blood, saliva and cerebrospinal fluid where they can be accessed for analysis. Our exosome-based assays unlock the ability to identify proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive "liquid biopsies". Additional information can be found at www.ExosomeSciences.com.

About Aethlon Medical
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com or www.ExosomeSciences.com.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more...



Wednesday, September 3, 2014

GenSpera (OTCQB:GNSZ) Announces Generic Name “Mipsagargin” for Lead Drug Candidate G-202 per Recommendation by World Health Organization



Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces Generic Name “Mipsagargin” for Lead Drug Candidate G-202 per Recommendation by World Health Organization

Mipsagargin Contains New Pre-Stem “Gargin”, Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market

SAN ANTONIO, Texas, September 3, 2014 – (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the World Health Organization’s (WHO) International Nonproprietary Name (INN) group has recommended the generic name “mipsagargin” (mip sa gar’ jin) for its lead drug candidate, also known as G-202, currently in Phase II clinical trials for hepatocellular carcinoma (liver cancer) and glioblastoma (brain cancer). Mipsagargin was also recommended by the United States Adopted Names Council (USAN) of the American Medical Association.

Craig Dionne, PhD, GenSpera's CEO, spoke to the significance of this issuance, “We are pleased that the INN division of WHO and the USAN Council recognized the unique nature of mipsagargin by affording it the new suffix, or pre-stem, of “gargin.” The WHO issues approximately 160 name recommendations per year with only 1-2% having new suffixes. New suffixes are generally given to compounds with a unique mechanism of action or structure and serve to define such compound as the first in a possible new class of pharmacological agents. We believe mipsagargin’s name recommendation is the result of G-202’s novel nature and our innovative approaches to cancer therapy.”

GenSpera recently released interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of sorafenib. Data showed 80% of patients treated with mipsagargin had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at four months on study. In addition, imaging analysis demonstrated an impressive blockade of tumor blood flow in the single patient evaluated by this method to date.

About Nonproprietary Names
Obtaining a nonproprietary (generic) name is a required part of bringing a new drug to market. The generic names of pharmacologically-related substances demonstrate their relationship by using a common "stem". Using common stems, medical practitioners, pharmacists, or people dealing with pharmaceutical products are able to recognize that the substance belongs to a group of substances having similar pharmacological activity. The generic name mipsagargin includes a novel pre-stem, “gargin”, indicating that it is unlike any named drug currently or previously on the market or in development. The pre-stem “gargin” may become an established stem over time, usually as other later developed drugs are recognized to be related in structure or activity to mipsagargin.

Each International Nonproprietary Name is a unique name that is globally recognized and is public property.


About GenSpera
GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types.

Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company’s website: www.genspera.com or follow us on Twitter @GenSperaNews.

Company presentations are available at: http://www.genspera.com/

Watch the Corporate Video:

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera’s periodic reports filed with the Securities and Exchange Commission.

CONTACT:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.  (210) 479-8112                                     

Investors: 
Steve Gersten
Capital Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920

Media:
Dawn Van Zant
(800) 665 0411

Visit this company: www.genspera.com

More info on GNSZ at Investorideas.com Visit: http://www.investorideas.com/CO/GNSZ/

Disclaimer/Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18, 2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/









Tuesday, September 2, 2014

Aethlon Medical (OTCQB: AEMD) Announces Receipt of IRB Approval to Initiate Hemopurifier™ Clinical Studies

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Receipt of IRB Approval to Initiate Hemopurifier™ Clinical Studies

SAN DIEGO - September 2, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal review board (IRB) approval to initiate human clinical studies of Hemopurifier® therapy at DaVita MedCenter Dialysis located in Houston, Texas.



Aethlon previously disclosed that the United States Food and Drug Administration (FDA) had approved an Investigational Device Exemption (IDE) that would allow for the initiation of Hemopurifier® feasibility studies in the United States. As a result of the independent IRB approval, the Company is now permitted to initiate the IDE approved study. Enrollment of patients who meet the study inclusion/exclusion criteria is expected to begin in the coming weeks. The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients.

Upon receipt of IDE approval from FDA, Aethlon initiated discussions with various clinical partner candidates. On February 26, 2014, the Company disclosed that it had reached an agreement in principle with DaVita Clinical Research® (DCR) and subsequently disclosed that it had completed a definitive agreement with DCR on May 20, 2014. DCR is a specialty contract research organization (CRO) with experience in conducting more than 300 early phase clinical trials. As a subsidiary of DaVita Healthcare Partners Inc, DCR has access to one third of the total U.S. ESRD patient population and maintains a network that exceeds 150 investigative physicians' practices at more than 250 clinical sites.

Aethlon further disclosed that Dr. Stephen Z. Fadem had been named Principal Investigator of the IDE approved study. Dr. Fadem is Chief Medical Officer at Kidney Associates, PLLC and the Medical Director for the Houston Kidney Center Integrated Service Network at DaVita Kidney Care, a division of DaVita HealthCare Partners Inc.

Under the feasibility study protocol, Aethlon will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier® therapy in an infectious disease model. Upon successful completion of the feasibility study, Aethlon plans to conduct pivotal efficacy studies required for market clearance to treat HCV and other chronic viral indications. Previous clinical studies of Hemopurifier® therapy have been conducted in HIV and HCV-infected individuals at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India.

Aethlon's feasibility study will also contribute safety data to advance the Hemopurifier® as a broad-spectrum countermeasure against high-risk bioterror and pandemic threats, which are so lethal they do not allow for the administration of clinical efficacy studies. In this regard, the Company is pursuing Emergency Use Authorization (EUA) approvals based on previous human treatment outcomes and pre-clinical validations against a broad-spectrum of viral pathogens.

Previously, in vitro studies of bioterror and pandemic threats have verified Hemopurifier® capture of ebola hemorrhagic virus, dengue hemorrhagic virus, lassa hemorrhagic virus, H5N1 avian influenza (bird flu), the reconstructed 1918 influenza virus (r1918), 2009 H1N1 influenza virus (swine flu), West Nile virus, and monkeypox, which serves as a model for human smallpox infection. These studies were conducted with leading government and non- government research organizations, including The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), The Centers for Disease Control and Prevention (CDC), The National Institute of Virology (NIV), The Battelle Biomedical Research Center (BBRC) and The Southwest Foundation for Biomedical Research (SFBR).

Aethlon also disclosed that it may pursue investigate Humanitarian Use Device (HUD) pathways for orphan indications that affect fewer than 4,000 individuals in the U.S. each year.


About Aethlon Medical
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com or www.ExosomeSciences.com.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
James A. Joyce 
Chairman and CEO
 
858.459.7800 x301
 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer
 
858.459.7800 x300
 
jfrakes@aethlonmedical.com

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp  
Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Become an Investorideas.com Member and access our 14 online stock directories 24/7 -mining stocks, oil and gas stocks and more...